1 Diosmectite is a natural silicate effectively used in the treatment of infectious diarrhoea. Its antidiarrhoeal properties involve adsorption of toxins and bacteria and modifications of the rheological characteristics of gastrointestinal mucus. Hence, the aim of this study was to test the intestinal anti-inflammatory activity of diosmectite. 2 Diosmectite (500 mg kg À1 day À1 , p.o.) was administered as a post-treatment to rats with chronic trinitrobenzene sulphonic acid colitis. Colonic status was checked 1 and 2 weeks after colitis induction by macroscopic, histological and biochemical examination. 3 Diosmectite post-treatment resulted in amelioration of the morphological signs (intestinal weight, macroscopic damage, necrosed area, histology) and biochemical markers (myeloperoxidase activity, glutathione levels, MUC2 expression, inducible nitric oxide synthase and interleukin-1b (IL-1b) and leukotriene B 4 synthesis), as well as in the reduction of the severity of diarrhoea. The effect of the clay was comparable to that of sulphasalazine (50 mg kg À1 day À1 ). 4 Diosmectite exhibited a dose-dependent capacity to adsorb proteins in vitro as well as a dosedependent inhibitory effect on the basolateral secretion of IL-8 by lipopolysaccharide (LPS)-stimulated HT29 cells. 5 Diosmectite had a dose-dependent inhibitory effect on IL-1b production by LPS-stimulated THP-1 cells. 6 The effect of diosmectite on MUC2 was post-transcriptional, since mRNA levels were unaffected. However, diosmectite is able to upregulate MUC2 mRNA levels in HT29-MTX cells. 7 Diosmectite has anti-inflammatory activity administered as a post-treatment. Possible mechanisms include adsorption of luminal antigens, increase of colonic mucin levels and possibly a direct modulatory action of cytokine production by mucosal cells.

No abstract

Crohn's disease and ulcerative colitis are the two most common categories of inflammatory bowel disease (IBD), which are characterized by chronic inflammation of the intestine that comprises the patients' life quality and requires sustained pharmacological and surgical treatments. Since their aetiology is not completely understood, nonfully efficient drugs have been developed and those that show effectiveness are not devoid of quite important adverse effects that impair their long-term use. Therefore, many patients try with some botanical drugs, which are safe and efficient after many years of use. However, it is necessary to properly evaluate these therapies to consider a new strategy for human IBD. In this report we have reviewed the main botanical drugs that have been assessed in clinical trials in human IBD and the mechanisms and the active compounds proposed for their beneficial effects.

The aerial parts of THYMUS HYEMALIS Lange were collected throughout its complete vegetative cycle (April 1981 to March 1982) from the same locality. The yield and composition of essential oil have been determined in eleven samples with special reference to the content of 1,8-cineole, camphor, thymol, and carvacrol. It was found that the yield and composition of the oil changed from month to month. On the basis of the results obtained, July might be proposed as the most suitable month for harvesting T. HYEMALIS, giving the maximum yield in essential oil, which is especially rich in terpenic hydrocarbons at this time. Maximum levels of 1,8-cineole in August, however, might warrent harvesting during this month as well.